How long is the recommended course of treatment with Epclusa?

The recommended course of treatment with Epclusa for most patients with chronic hepatitis C is typically 12 weeks. This duration has been established through clinical studies that demonstrate the effectiveness and safety of the medication over this time frame, allowing it to achieve sustained virologic response (SVR) in a high percentage of patients.

Epclusa is a combination of sofosbuvir and velpatasvir, which work together to target multiple stages of the hepatitis C virus lifecycle, contributing to its efficacy. While some patients may require varied treatment durations depending on factors like previous treatment history, genotype, and the presence of cirrhosis, for the general population, 12 weeks is the standard duration and is supported by clinical guidelines.

Other durations, such as 8, 10, or 16 weeks, are generally not recommended for initial treatment of hepatitis C with Epclusa, except in specific circumstances under close medical supervision, reflecting the clinical consensus on the importance of adhering to the 12-week regimen for optimal outcomes.